BioRestorative Therapies (BRTX) Interest Income - Total (2023 - 2025)
BioRestorative Therapies' (BRTX) quarterly Interest Income - Total came in at $34695.0 in Q4 2025, down 73.58% YoY from $131325.0 in Q4 2024, and down 41.53% on a QoQ basis from $59336.0 in Q3 2025.
BioRestorative Therapies (BRTX) Interest Income - Total (2023 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 3 years of Interest Income - Total data on file, last reported at $34695.0 in Q4 2025.
- Quarterly Interest Income - Total fell 73.58% year-over-year to $34695.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $270573.0 (down 56.63% YoY) and the FY2025 annual result came in at $270573.0, down 56.63% from the prior year.
- Interest Income - Total slipped to $34695.0 in Q4 2025, from $59336.0 in the prior quarter.
- In the past five years, Interest Income - Total ranged from a high of $402202.0 in Q4 2023 to a low of -$39292.0 in Q3 2023.
- A 3-year average of $121953.5 and a median of $117062.0 in 2024 frame the typical range for Interest Income - Total.
- Annual changes were most pronounced in 2024 — Interest Income - Total surged 520.98% — and 2025, when it plunged 73.58%.
- Tracing BRTX's Interest Income - Total over 3 years: stood at $402202.0 in 2023, then sank by 67.35% to $131325.0 in 2024, then slumped by 73.58% to $34695.0 in 2025.
- The last three Interest Income - Total figures came in at $34695.0 (Q4 2025), $59336.0 (Q3 2025), and $73743.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Income - Total (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | 34,695.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 34,695.00 |
| Dec 31, 2025 | 34,695.00 |
| Sep 30, 2025 | 59,336.00 |
| Sep 30, 2025 | 59,336.00 |
| Jun 30, 2025 | 73,743.00 |
| Jun 30, 2025 | 73,743.00 |
| Mar 31, 2025 | 102,799.00 |
| Mar 31, 2025 | 102,799.00 |
| Dec 31, 2024 | 131,325.00 |
| Dec 31, 2024 | 131,325.00 |
| Sep 30, 2024 | 165,411.00 |
| Sep 30, 2024 | 165,411.00 |
| Jun 30, 2024 | 175,469.00 |
| Jun 30, 2024 | 175,469.00 |
| Mar 31, 2024 | 151,596.00 |
| Mar 31, 2024 | 151,596.00 |
| Dec 31, 2023 | 402,202.00 |
| Dec 31, 2023 | 402,202.00 |
| Sep 30, 2023 | -39,292.00 |
| Sep 30, 2023 | -39,292.00 |